We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

104 hedge funds and large institutions have $929M invested in Revance Therapeutics, Inc. in 2015 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 45 increasing their positions, 17 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

417% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 6

165% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 17

117% more call options, than puts

Call options by funds: $5.64M | Put options by funds: $2.59M

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

44% more capital invested

Capital invested by funds: $644M → $929M (+$285M)

32% more funds holding

Funds holding: 79 → 104 (+25)

Holders
104
Holders Change
+25
Holders Change %
+31.65%
% of All Funds
2.73%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.1%
New
31
Increased
45
Reduced
17
Closed
6
Calls
$5.64M
Puts
$2.59M
Net Calls
+$3.04M
Net Calls Change
-$2.55M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$53.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$19.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
+$15M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$14.2M
5
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$12.4M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$2.33M
2
Goldman Sachs
Goldman Sachs
New York
-$2.28M
3
Franklin Resources
Franklin Resources
California
-$2.27M
4
Millennium Management
Millennium Management
New York
-$2.04M
5
Fidelity International
Fidelity International
Bermuda
-$1.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$4.4M +$1.1M +31,815 +33%
Millennium Management
27
Millennium Management
New York
$4.03M -$2.04M -58,951 -33%
EI
28
EAM Investors
California
$3.51M +$3.56M +102,800 New
Baird Financial Group
29
Baird Financial Group
Wisconsin
$2.82M +$455K +13,114 +19%
Principal Financial Group
30
Principal Financial Group
Iowa
$2.79M +$121K +3,481 +4%
DCM
31
Driehaus Capital Management
Illinois
$2.67M +$2.71M +78,078 New
UBV
32
United Bank (Virginia)
Virginia
$2.64M +$2.68M +77,177 New
EIM
33
Essex Investment Management
Massachusetts
$2.45M – – –
Susquehanna International Group
34
Susquehanna International Group
Pennsylvania
$2.42M +$1.26M +36,224 +105%
BIM
35
BlackRock Investment Management
Delaware
$2.18M +$294K +8,484 +15%
Charles Schwab
36
Charles Schwab
California
$2.17M +$576K +16,625 +35%
CCI
37
Columbus Circle Investors
$2.09M +$1.24M +35,734 +140%
OAM
38
Oxford Asset Management
United Kingdom
$1.99M +$2M +57,641 New
TCIM
39
TIAA CREF Investment Management
New York
$1.9M +$110K +3,187 +6%
Two Sigma Investments
40
Two Sigma Investments
New York
$1.65M +$1.67M +48,146 New
SCM
41
Suffolk Capital Management
New York
$1.64M +$1.66M +47,958 New
Ameriprise
42
Ameriprise
Minnesota
$1.43M +$1.45M +41,957 New
RFC
43
Russell Frank Company
Washington
$1.38M +$1.35M +38,974 New
AA
44
ALPS Advisors
Colorado
$1.26M -$17.8K -513 -1%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$1.16M +$190K +5,492 +19%
LCS
46
Levin Capital Strategies
New York
$1.11M -$393K -11,333 -26%
TC
47
TFS Capital
Pennsylvania
$1.01M +$1.02M +29,460 New
TA
48
Teachers Advisors
New York
$893K +$112K +3,243 +14%
State of New Jersey Common Pension Fund D
49
State of New Jersey Common Pension Fund D
New Jersey
$888K – – –
AllianceBernstein
50
AllianceBernstein
Tennessee
$864K +$107K +3,100 +14%
1
2
3 4 5

RVNC Hedge Fund Activity: Q4 2015 in Review

104 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2015, worth a combined $929M — up 44% from $644M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new RVNC positions and 6 closed out — a net gain of 25 holders — while 45 added to existing stakes and 17 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $53.4M. The largest seller was Jennison Associates, exiting entirely with an estimated $2.33M sold.

  • 104 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2015, up from 79 in Q3 2015.
  • Funds reported $929M of Revance Therapeutics, Inc. stock for Q4 2015, up 44% quarter-over-quarter.
  • 31 funds opened new Revance Therapeutics, Inc. positions in Q4 2015 and 6 closed out, a net change of +25 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q4 2015 was JP Morgan Chase, an estimated $53.4M added.
  • The largest Revance Therapeutics, Inc. seller in Q4 2015 was Jennison Associates, an estimated $2.33M sold.

Based on aggregated 13F filings for Q4 2015.